Search results
Targeting glutamine metabolism improves sarcoma response to radiation therapy in vivo -...
Nature· 1 day agoUsing primary mouse model of soft-tissue sarcoma (STS), authors show that sarcoma switches to glutamine metabolism ...
Immutep shares gain as CapitalOne sets $10 target on cancer drug potential By Investing.com
Investing.com· 4 days agoThe biotechnology company, which specializes in novel cancer treatments, is currently advancing...
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
Clinical Trials Arena via Yahoo Finance· 5 days agoApart from NIH, BrainUp, a non-profit organisation focusing on creating awareness on brain cancer,...
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoOur clinical development strategy is designed to create the opportunity for enva to broadly benefit patients with sarcoma in the frontline, adjuvant and neoadjuvant settings ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 hours agoSanta Barbara, CA, May 21, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to ...
Robert W. Baird Cuts Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Price Target to $2.00
ETF DAILY NEWS· 2 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price objective decreased by Robert W. Baird from $4.50 to $2.00 in a research note published on Wednesday morning, Benzinga ...
Local boy becomes published author through Make-A-Wish Foundation
The Columbus Dispatch via Yahoo News· 4 days agoChukwu, who has clear cell sarcoma − a rare, aggressive and malignant tumor that affects soft tissue...
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) PT Lowered to $2.00 at Robert W. Baird
ETF DAILY NEWS· 2 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price target reduced by Robert W. Baird from $4.50 to $2.00 in a report released on Wednesday, Benzinga reports. Robert W. Baird ...
Column: No Mow May should be 'No Spray May': Let's stop abusing Mother Earth
The Palm Beach Post via Yahoo News· 5 days agoIs no one paying any attention? People believe that chemicals on the market have been tested for...
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA)...
WTRF Wheeling· 5 days agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
